We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
-9%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$646M
AUM Growth
-$158M
Cap. Flow
-$46.8M
Cap. Flow %
-7.25%
Top 10 Hldgs %
94.51%
Holding
15
New
–
Increased
–
Reduced
3
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$35.8M
2
AKRO
Akero Therapeutics
AKRO
+$10.9M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$25

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRON icon
1
Disc Medicine
IRON
$2.93B
$129M 19.98%
2,745,335
-716,449
-21% -$35.8M
DAWN
2
DELISTED
Day One Biopharmaceuticals
DAWN
$93.4M 14.46%
7,608,394
– –
DYN icon
3
Dyne Therapeutics
DYN
$4.63B
$88.6M 13.72%
9,885,449
– –
KYMR icon
4
Kymera Therapeutics
KYMR
$8.26B
$81.4M 12.61%
5,858,262
– –
THRD
5
DELISTED
Third Harmonic Bio
THRD
$69.7M 10.8%
10,907,859
– –
REPL icon
6
Replimune Group
REPL
$960M
$35.9M 5.56%
2,098,300
– –
VIGL
7
DELISTED
Vigil Neuroscience
VIGL
$31.5M 4.87%
5,836,874
– –
GBIO
8
DELISTED
Generation Bio
GBIO
$31.4M 4.86%
827,948
– –
JBIO
9
Jade Biosciences
JBIO
$1.15B
$27.7M 4.29%
58,264
– –
IMA
10
ImageneBio Inc
IMA
$63M
$21.7M 3.37%
418,182
– –
AKRO
11
DELISTED
Akero Therapeutics
AKRO
$18.2M 2.81%
359,251
-235,000
-40% -$10.9M
TECX
12
Tectonic Therapeutic
TECX
$526M
$6.99M 1.08%
378,448
– –
XLO icon
13
Xilio Therapeutics
XLO
$59.4M
$5.82M 0.9%
197,096
– –
DNTH icon
14
Dianthus Therapeutics
DNTH
$5.75B
$3.24M 0.5%
236,979
-2
-0% -$25
SPRO icon
15
Spero Therapeutics
SPRO
$68.9M
$1.23M 0.19%
1,013,438
– –

Similar funds

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AT
Avenir Tech Hong Kong $790M AUM 17.91% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
VH
V3 Holding Rye, New York $789M AUM 459.57% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
VCM
Vision Capital Management Portland, Oregon $792M AUM 18.17% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Atlas Venture Life Science Advisors held 15 positions worth $646M, down 20% from $804M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Atlas Venture Life Science Advisors withdrew a net $46.8M in Q3 2023, reducing 3 holdings. Its largest reduction was Disc Medicine, cutting an estimated $35.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Atlas Venture Life Science Advisors's biggest Q3 2023 reduction was Disc Medicine, cutting an estimated $35.8M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 95% of its $646M portfolio in Q3 2023.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 0 in Q3 2023.
  • Atlas Venture Life Science Advisors's portfolio value fell 20% quarter-over-quarter to $646M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.